Don’t miss out on an opportunity to join the trial. Capacity of 150 patients almost reached.
Screening for the PellePharm Gorlin study will end next Friday, November 8th 2019. As a result of unforeseen issues in the UK the screening period at sites in London, Oxford, Salford and Glasgow has been extended to Friday, November 15th 2019.
All sites will continue to enrol patients for the trial until the deadline. Patients screened through November 15th and randomized by November 30th may be entered into the study.
This is a global study of the efficacy and safety of Patidegib Topical Gel, 2%, applied topically twice daily to the face of adult participants with Gorlin syndrome. For more information about the trail and eligibility criteria visit clinicaltrials.gov